News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aprea Therapeutics Inc
(NQ:
APRE
)
3.720
-0.065 (-1.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aprea Therapeutics Inc
< Previous
1
2
3
4
5
Next >
APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 12, 2024
APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
June 21, 2024
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
June 17, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics: Q4 Earnings Insights
March 26, 2024
Via
Benzinga
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
May 28, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024
May 14, 2024
APRE stock results show that Aprea Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
May 14, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
May 13, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024
New role enhances company’s strong leadership team and solidifies commitment to ongoing clinical innovation
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
April 10, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 04, 2024
Via
Benzinga
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023
March 26, 2024
APRE stock results show that Aprea Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
March 26, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?
March 11, 2024
FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation in 2024, focusing on Cyclin E cancers. $34 million private placement to fund...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 11, 2024
Via
Benzinga
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
March 11, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
March 11, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
March 05, 2024
Four Poster Presentations, Including Posters on ATRN-119 (novel macrocyclic ATR inhibitor) and APR-1051 (next generation WEE1 kinase inhibitor)
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
February 06, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
January 30, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
January 04, 2024
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 09, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
A Look Into Healthcare Sector Value Stocks
October 30, 2023
Via
Benzinga
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
October 24, 2023
Event featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ET
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
October 16, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
5 Value Stocks To Watch In The Healthcare Sector
September 25, 2023
Via
Benzinga
5 Value Stocks To Watch In The Healthcare Sector
September 04, 2023
Via
Benzinga
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
August 24, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
August 10, 2023
From
Aprea Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.